OMass Therapeutics Series C: €275M

Oct 16, 2026Public sources — Collected from public sources, not yet cross-checked.

OMass Therapeutics raised €275 million (about $308.22 million) in a series c round led by Bain Capital Life Sciences and Forbion and Novo Holdings, announced Oct. 16.

Facts

Company: OMass Therapeutics
Amount: €275 million (about $308.22 million)
Currency: EUR
Stage: Series C
Announced: Oct 16, 2026
Instrument: Equity
FX rate: 1 EUR = 1.1208 USD on Oct 15, 2026

Investors

Led by: Bain Capital Life Sciences Forbion Novo Holdings
Participants: Janus Henderson Investors SV Health Investors Jefferson Life Sciences Syncona Oxford Science Enterprises GV Northpond Ventures Sanofi Ventures British Business Bank University of Oxford

Use of funds

Advance lead programme OMS1620 to Phase 2 and generate data for SLC15A4 inhibitor.

As stated by the company.

Sources

1.Oxford spin-out OMass Therapeutics lands €275 million to bring novel small-molecule therapies closer to patients — EU-Startups, Oct 16, 2026

Public sources — Collected from public sources, not yet cross-checked.Last verified Oct 16, 2026